Fleebs-Logo
Details werden geladen...

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | The Manila Times

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -

Ähnliche Seiten

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/lynozyfic-linvoseltamab-monotherapy-demonstrates-deep-and-rapid-responses-in-all-treated-patients-with-second-line-plus-systemic-amyloid-light-chain-amyloidosis/2349703

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/lynozyfic-linvoseltamab-monotherapy-demonstrates-deep-and-rapid-responses-in-all-treated-patients-with-second-line-plus-systemic-amyloid-light-chain-amyloidosis/2349703
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/remix-therapeutics-announces-positive-data-from-phase-12-aria-study-of-first-in-class-myb-mrna-degrader-rem-422-in-patients-with-adenoid-cystic-carcinoma-acc-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349708

Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical ...

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/remix-therapeutics-announces-positive-data-from-phase-12-aria-study-of-first-in-class-myb-mrna-degrader-rem-422-in-patients-with-adenoid-cystic-carcinoma-acc-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349708
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer/2345762

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer | The Manila Times

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer/2345762
https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/novartis-advances-rlt-innovation-and-reinforces-leadership-in-prostate-cancer-breast-cancer-and-hematology-with-new-data-at-asco-and-eha/2348825

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA | The Manila Times

https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/novartis-advances-rlt-innovation-and-reinforces-leadership-in-prostate-cancer-breast-cancer-and-hematology-with-new-data-at-asco-and-eha/2348825
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/roche-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer/2346752

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer | The Manila Times

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/roche-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer/2346752
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/akari-therapeutics-reports-breakthrough-preclinical-data-demonstrating-synergistic-activity-of-aktx-101-with-kras-inhibition-in-kras-mutated-pancreatic-cancer-models/2349705

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/akari-therapeutics-reports-breakthrough-preclinical-data-demonstrating-synergistic-activity-of-aktx-101-with-kras-inhibition-in-kras-mutated-pancreatic-cancer-models/2349705